While the Omicron variant of the CCP (Chinese Communist Party) virus seems to be causing less severe disease than the Delta variant, it’s still landing some people in hospitals, highlighting the need for effective treatment before cases progress to that stage, a frontline doctor says.
Dr. Syed Haider has treated more than 4,000 COVID-19-positive patients so far during the pandemic. Just five ended up going to a hospital, and none have died.
The doctor said his preferred treatments include many off-label medications along with vitamins and supplements.
“Vitamin D is really important, ivermectin is important, fluvoxamine, hydroxychloroquine also works, it’s just a lot of people have been convinced that it doesn’t at this point, and are scared off of trying it,” Haider told NTD’s “Capitol Report.” “But I prefer ivermectin, fluvoxamine, Vitamin D, Vitamin C, quercetin, zinc.”
Ivermectin is an anti-parasitic that has had mixed results against COVID-19 in clinical trials and isn’t advised by the Food and Drug Administration to treat the disease. Fluvoxamine is an antidepressant that’s gaining popularity for use against COVID-19. Hydroxychloroquine is an anti-malarial that has shown some success in treating the disease. Quercetin is a plant pigment that’s not widely known yet as a treatment for COVID-19.
Haider has also recommended flax seed oil.
“One really easy thing that anyone can do is just follow the directions on a bottle of hydrogen peroxide, you can get this at the store, can dilute it down to 1 percent swish swish it through your nose, or swish it through your mouth and drip it into your nose or use a neti pot to rinse out your nose. And it’s not uncomfortable, it shouldn’t be burning, if it’s burning, you would want to dilute it a little bit more, and that kills the virus on contact,” he said.
Haider’s list differs from the National Institutes of Health’s recently updated treatment recommendations for non hospitalized COVID-19 patients.
The agency recommends using Pfizer’s COVID-19 pill, known as paxlovid; Merck’s pill, called molnupiravir; GlaxoSmithKline’s monoclonal antibody treatment, sotrovimab; or Gilead Sciences’s remdesivir, administered through IV over multiple days.
The recommendations stem from studies that demonstrate the therapeutics’ effectiveness, the agency said.
Haider, however, doesn’t agree with the remdesivir recommendation, noting it’s never received an endorsement from the World Health Organization and that is has the side effect of causing kidney failure.